文献速递胸部肿瘤

奥拉帕利联合替莫唑胺治疗复发性小细胞肺癌

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
PubMed 文献 · Cancer Discov · 2019-08-15

该I/II期试验在既往治疗的小细胞肺癌患者中评估奥拉帕利联合替莫唑胺(OT),确定II期推荐剂量为奥拉帕利200mg每日两次联合替莫唑胺75mg/m2每日,每21天周期用7天,扩展至50例。确认的客观缓解率为41.7%(20/48可评估),中位无进展生存期4.2个月(95%CI 2.8-5.7),中位总生存期8.5个月(95%CI 5.1-11.3)。患者来源异种移植(PDX)再现临床反应,低基线炎症反应基因表达与OT及一线化疗交叉耐药相关。

要点

  • OT方案在复发性SCLC显示41.7%的确认客观缓解率。
  • 中位PFS 4.2个月,中位OS 8.5个月。
  • 低基线炎症反应基因表达与OT及一线化疗交叉耐药相关。

核心结论

  • 奥拉帕利联合替莫唑胺在复发性小细胞肺癌中显示出显著临床活性,并发现可预测反应的分子特征。

研究设计与样本

  • I/II期试验,确定II期推荐剂量后扩展至50例既往治疗的小细胞肺癌患者。

主要发现

  • 确认的客观缓解率为41.7%(20/48可评估)。
  • 中位无进展生存期为4.2个月(95%CI 2.8-5.7)。
  • 中位总生存期为8.5个月(95%CI 5.1-11.3)。
  • 患者来源异种移植再现临床OT反应,并揭示低基线炎症反应基因表达与OT及一线化疗交叉耐药相关。

关键数值与推荐

  • II期推荐剂量为奥拉帕利200mg口服每日两次联合替莫唑胺75mg/m2每日,每21天周期第1-7天给药。

临床怎么用

  • OT方案可作为复发性小细胞肺癌的一种有前景的治疗策略,低基线炎症反应基因表达可能提示交叉耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. We established a recommended phase II dose of olaparib 200 mg orally twice daily with temozolomide 75 mg/m2 daily, both on days 1 to 7 of a 21-day cycle, and expanded to a total of 50 patients. The confirmed overall response rate was 41.7% (20/48 evaluable); median progression-free survival was 4.2 months [95% confidence interval (CI), 2.8-5.7]; and median overall survival was 8.5 months (95% CI, 5.1-11.3). Patient-derived xenografts (PDX) from trial patients recapitulated clinical OT responses, enabling a 32-PDX coclinical trial. This revealed a correlation between low basal expression of inflammatory-response genes and cross-resistance to both OT and standard first-line chemotherapy (etoposide/platinum). These results demonstrate a promising new therapeutic strategy in SCLC and uncover a molecular signature of those tumors most likely to respond. SIGNIFICANCE: We demonstrate substantial clinical activity of combination olaparib/temozolomide in relapsed SCLC, revealing a promising new therapeutic strategy for this highly recalcitrant malignancy. Through an integrated coclinical trial in PDXs, we then identify a molecular signature predictive of response to OT, and describe the common molecular features of cross-resistant SCLC.See related commentary by Pacheco and Byers, p. 1340.This article is highlighted in the In This Issue feature, p. 1325.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Farago AF, Yeap BY, Stanzione M, et al. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019. PMID: 31416802. doi:10.1158/2159-8290.CD-19-0582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。